Moreover, we also showed that the characteristic gene mutation and expression signatures that distinguished short- from long-lived DNMT3A-mutant TCGA AML patients contain relevant information that can be used to classify other independent DNMT3A-mutant AML patients as short- or long-lived. This evidence concerns the gene DNMT3A and acute myeloid leukemia.